A study testing whether 177Lu-DTPA-omburtamab is safe for children and teens with brain cancer
Official title: A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing if a treatment called 177Lu-DTPA-omburtamab is safe for young people whose cancer is in the brain or spinal cord.
Read our full plain-language summary
What the trial team says
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
Key facts
- Registry number
- NCT07698899
- Stage of testing
- Phase 1
- Conditions studied
- Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
Where it is running
This trial lists 7 sites.
-
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities) (Basking Ridge)
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) (Middletown)
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) (Montvale)
-
New York
- Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) (Commack)
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) (Harrison)
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) (New York)
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities) (Uniondale)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.